More Company News

MaxCyte

Q2 and H121 results and preliminary FY21 revenue guidance
13 Sep 2021Read More

MaxCyte

Clinical and commercial licence with Sana Biotechnology
09 Aug 2021Read More

MaxCyte

Closing of offering
03 Aug 2021Read More

MaxCyte

Full exercise of over-allotment option
02 Aug 2021Read More

MaxCyte

Pricing of upsized offering and approval to list on NASDAQ
30 Jul 2021Read More

MaxCyte

Launch of offering and application to list on NASDAQ
26 Jul 2021Read More

MaxCyte

S-1 financial information & directorate change
12 Jul 2021Read More

MaxCyte

Public filing of Registration Statement with SEC
12 Jul 2021Read More

MaxCyte

Strategic platform licence with Celularity
25 May 2021Read More

MaxCyte

Proposed dual-listing on NASDAQ
14 May 2021Read More

1 2 3 4 … 8
Return to MaxCyte
© 2019-21 Trinity Delta. All rights reserved. Trinity Delta is regulated by the Financial Conduct Authority (Reference number: 725161).